Bacterial Conjunctivitis - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 56 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Bacterial Conjunctivitis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Bacterial Conjunctivitis - Pipeline Review, H2 2014', provides an overview of the Bacterial Conjunctivitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bacterial Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacterial Conjunctivitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bacterial Conjunctivitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Bacterial Conjunctivitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Bacterial Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bacterial Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bacterial Conjunctivitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bacterial Conjunctivitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bacterial Conjunctivitis Overview 6
Therapeutics Development 7
Pipeline Products for Bacterial Conjunctivitis - Overview 7
Pipeline Products for Bacterial Conjunctivitis - Comparative Analysis 8
Bacterial Conjunctivitis - Therapeutics under Development by Companies 9
Bacterial Conjunctivitis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Bacterial Conjunctivitis - Products under Development by Companies 13
Bacterial Conjunctivitis - Companies Involved in Therapeutics Development 14
Cellceutix Corporation 14
China Grand Wuhan General Pharmaceutical Research Institute 15
Daiichi Sankyo Company, Limited 16
InSite Vision Incorporated 17
NovaBay Pharmaceuticals, Inc. 18
Ocular Therapeutix, Inc. 19
Bacterial Conjunctivitis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 28
auriclosene - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
brilacidin - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ISV-405 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
levofloxacin - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
moxifloxacin hydrochloride SR - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
NVC-638 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
NVC-704 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
NVC-727 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
XY-0911AQ2 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Bacterial Conjunctivitis - Recent Pipeline Updates 40
Bacterial Conjunctivitis - Dormant Projects 52
Bacterial Conjunctivitis - Product Development Milestones 53
Featured News & Press Releases 53
Oct 03, 2013: Lupin launches Generic ZYMAXID Ophthalmic solution in the US 53
Aug 28, 2013: Lupin Receives FDA Approval For Gatifloxacin Eye Drops 53
Jul 01, 2013: Lupin Gets FDA Tentative Approval For Gatifloxacin Eye Drops 53
Dec 17, 2009: NovaBay To Receive Increase In Funding And Support From Alcon 53
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 56
Disclaimer 56

List of Tables
Number of Products under Development for Bacterial Conjunctivitis, H2 2014 7
Number of Products under Development for Bacterial Conjunctivitis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Bacterial Conjunctivitis - Pipeline by Cellceutix Corporation, H2 2014 14
Bacterial Conjunctivitis - Pipeline by China Grand Wuhan General Pharmaceutical Research Institute, H2 2014 15
Bacterial Conjunctivitis - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 16
Bacterial Conjunctivitis - Pipeline by InSite Vision Incorporated, H2 2014 17
Bacterial Conjunctivitis - Pipeline by NovaBay Pharmaceuticals, Inc., H2 2014 18
Bacterial Conjunctivitis - Pipeline by Ocular Therapeutix, Inc., H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Mechanism of Action, H2 2014 24
Number of Products by Stage and Route of Administration, H2 2014 26
Number of Products by Stage and Molecule Type, H2 2014 27
Bacterial Conjunctivitis Therapeutics - Recent Pipeline Updates, H2 2014 40
Bacterial Conjunctivitis - Dormant Projects, H2 2014 52